KUCHARCHUK ANDREW ALBERT 4
4 · OncBioMune Pharmaceuticals, Inc · Filed Jun 9, 2020
Insider Transaction Report
Form 4
KUCHARCHUK ANDREW ALBERT
DirectorCFO & President
Transactions
- Award
Series D-2 Convertible Preferred Stock
2020-06-05+241→ 241 totalExercise: $0.00→ Common Stock (2,410,000 underlying)
Footnotes (3)
- [F1]The Series D-2 Convertible Preferred Stock will automatically convert into shares of Common Stock upon the filing of an amendment to the Issuer's Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of shares of Common Stock the Issuer is authorized to issue.
- [F2]The Series D-2 Convertible Preferred has no expiration date.
- [F3]No additional consideration need be paid for the automatic conversion to common stock to take place.